Literature DB >> 17709381

Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.

JuanJuan Yin1, Claire Pollock, Kirsten Tracy, Monika Chock, Philip Martin, Michael Oberst, Kathleen Kelly.   

Abstract

A hallmark of metastasis is organ specificity; however, little is known about the underlying signaling pathways responsible for the colonization and growth of tumor cells in target organs. Since tyrosine kinase receptor activation is frequently associated with prostate cancer progression, we have investigated the role of a common signaling intermediary, activated Ras, in prostate cancer metastasis. Three effector pathways downstream of Ras, Raf/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase, and Ral guanine nucleotide exchange factors (RalGEFs), were assayed for their ability to promote the metastasis of a tumorigenic, nonmetastatic human prostate cancer cell line, DU145. Oncogenic Ras promoted the metastasis of DU145 to multiple organs, including bone and brain. Activation of the Raf/ERK pathway stimulated metastatic colonization of the brain, while activation of the RalGEF pathway led to bone metastases, the most common organ site for prostate cancer metastasis. In addition, loss of RalA in the metastatic PC3 cell line inhibited bone metastasis but did not affect subcutaneous tumor growth. Loss of Ral appeared to suppress expansive growth of prostate cancer cells in bone, whereas homing and initial colonization were less affected. These data extend our understanding of the functional roles of the Ral pathway and begin to identify signaling pathways relevant for organ-specific metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709381      PMCID: PMC2169046          DOI: 10.1128/MCB.00955-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  The small GTPase RalA targets filamin to induce filopodia.

Authors:  Y Ohta; N Suzuki; S Nakamura; J H Hartwig; T P Stossel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin.

Authors:  A Miric; M Banks; D Allen; J Feighan; C A Petersilge; J R Carter; J T Makley
Journal:  J Surg Oncol       Date:  1998-04       Impact factor: 3.454

3.  Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

Authors:  Kian-Huat Lim; Kevin O'Hayer; Stacey J Adam; S Disean Kendall; Paul M Campbell; Channing J Der; Christopher M Counter
Journal:  Curr Biol       Date:  2006-12-19       Impact factor: 10.834

4.  Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Authors:  J A Nemeth; J F Harb; U Barroso; Z He; D J Grignon; M L Cher
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

Review 5.  Osteoblasts in prostate cancer metastasis to bone.

Authors:  Christopher J Logothetis; Sue-Hwa Lin
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

6.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

Authors:  Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 7.  Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis.

Authors:  F W Orr; H H Wang
Journal:  Surg Oncol Clin N Am       Date:  2001-04       Impact factor: 3.495

Review 8.  Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

Authors:  Gretchen A Repasky; Emily J Chenette; Channing J Der
Journal:  Trends Cell Biol       Date:  2004-11       Impact factor: 20.808

9.  Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice.

Authors:  J M Connolly; D P Rose
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

Review 10.  Parathyroid hormone-related protein and bone metastases.

Authors:  T A Guise
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

View more
  65 in total

1.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 2.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

3.  Mouse models for studying prostate cancer bone metastasis.

Authors:  Jinlu Dai; Janine Hensel; Ning Wang; Marianna Kruithof-de Julio; Yusuke Shiozawa
Journal:  Bonekey Rep       Date:  2016-02-17

4.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.

Authors:  Philip Martin; Yen-Nien Liu; Rachel Pierce; Wassim Abou-Kheir; Orla Casey; Victoria Seng; Daniel Camacho; R Mark Simpson; Kathleen Kelly
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

5.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

6.  Mechanisms regulating colorectal cancer cell metastasis into liver (Review).

Authors:  Ketao Jin; Weili Gao; Yanyan Lu; Huanrong Lan; Lisong Teng; Feilin Cao
Journal:  Oncol Lett       Date:  2011-09-30       Impact factor: 2.967

7.  Synthesis of novel Ral inhibitors: An in vitro and in vivo study.

Authors:  Chao Yan; Dan Theodorescu; Bettina Miller; Amit Kumar; Vijay Kumar; David Ross; Michael F Wempe
Journal:  Bioorg Med Chem Lett       Date:  2016-10-12       Impact factor: 2.823

8.  Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Authors:  W-Y Chen; Y-C Tsai; M K Siu; H-L Yeh; C-L Chen; J J Yin; J Huang; Y-N Liu
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

9.  Ral activation promotes melanomagenesis.

Authors:  P A Zipfel; D C Brady; D F Kashatus; B D Ancrile; D S Tyler; C M Counter
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

10.  Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.

Authors:  Juan JuanYin; Kirsten Tracy; Luhua Zhang; Jeeva Munasinghe; Erik Shapiro; Alan Koretsky; Kathleen Kelly
Journal:  Clin Exp Metastasis       Date:  2009-03-11       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.